PDGFR antagonists(Platelet-derived growth factor receptor antagonists), VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [2]

Active Indication-

Inactive Indication

Advanced Colorectal AdenocarcinomaAdvanced Hepatocellular CarcinomaAdvanced Lung Non-Small Cell Carcinoma+ [10]

Originator Organization

AbbVie, Inc.

Active Organization-

Inactive Organization

AbbVie, Inc.

Abbott Laboratories

Genentech, Inc.

+ [1]

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC21H18FN5O

InChIKeyMPVGZUGXCQEXTM-UHFFFAOYSA-N

CAS Registry796967-16-3

Clinical Trials associated with Linifanib

NCT03481842

/ WithdrawnPhase 1/2

Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis

Background:
Endometriosis is a chronic gynecological disease with the growth of endometrial tissue outside the endometrium. In all its properties, this tissue is similar to the mucous membrane of the uterus.
Types of endometriosis:
Endometriosis is divided into genital and extragenital. Genital endometriosis is internal and external. When the inner is affected by the uterus, with the external - the ovaries, tubes, vagina and external genital organs are affected. Extragenital endometriosis can affect various organs of the abdominal cavity.
Drug treatment does not show high effectiveness. Surgery / laparoscopic is currently considered the gold standard treatment for this problem, including infertility treatment.
The purpose of our studies is to achieve substantial results with respect to tolerability, safety and clinical efficacy of vaginal suppository ELTA for treatment of the endometriosis.
Methods:
Phase I clinical trial to be conducted at Cancer Center to hold under the aegis UniversitätsSpital Zürich from May 2018 to September 2018.
Ninety-four patients with the form of genital endometriosis will take part in the studies. The study was approved by the Ethics Committee at the Cancer Institute no C99884.01FH339

Start Date10 Oct 2021

Sponsor / Collaborator

BioGene Pharmaceutical Ltd.

NCT01506934

/ TerminatedPhase 1

A Phase 1, Open Label, Randomized, Adaptive, Cross-Over Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

A pharmacokinetic study to compare 2 clinical formulations of linifanib and the effect of food on the pharmacokinetics of linifanib.

Start Date01 Oct 2011

Sponsor / Collaborator

Abbott Laboratories

NCT01286974

/ TerminatedPhase 1

Disposition of [14C]ABT-869 in Patients With Solid Tumors Following a Single Oral Dose Administration

A pharmacokinetic study to access how the body absorbs and removes linifanib in male patients with advanced solid tumors.

Start Date01 Aug 2011

Sponsor / Collaborator

Abbott Laboratories

100 Clinical Results associated with Linifanib

100 Translational Medicine associated with Linifanib

100 Patents (Medical) associated with Linifanib

307

Literatures (Medical) associated with Linifanib

01 Dec 2024·JOURNAL OF CONTROLLED RELEASE

Surface-engineered mesenchymal stem cell for refractory asthma therapy: Reversing airway remodeling

Article

Author: Zhao, Yu-Chen ; Han, Meng-Meng ; Jeong, Jee-Heon ; Wang, Guang-Ji ; Wang, Jing ; Tang, Ling ; Jiang, Hu-Lin ; He, Xing-Yue ; Xing, Lei ; Wang, Yi ; Wei, Ning ; Zhou, Fang

In the development of asthma, subepithelial fibrosis and vascular proliferation cause airway remodeling and narrowing, leading to disease deterioration and respiratory failure. In the clinic, the treatment of asthma was aimed at reducing the frequency of acute asthma attacks through inhaled corticosteroids (ICSs). However, ICSs cannot prevent the progression into refractory asthma due to the formation of airway remodeling mainly by subepithelial fibrosis and angiogenesis surrounding the tracheal lumen. Herein, we constructed surface-engineered mesenchymal stem cells (MSCs/PVLA) via the bioconjugation of MSCs and reactive oxygen species-responsive polymeric micelles loaded with vactosertib (VST) and linifanib (LFN) for treating refractory asthma through reversing airway remodeling. MSCs/PVLA migrated to the tracheal lumen due to the inflammation tropism of MSCs, and subsequently released VST and LFN could inhibit the formation of airway remodeling by preventing subepithelial fibrosis and angiogenesis. Meanwhile, MSCs reduced inflammatory cell infiltration and cytokine secretion to regulate the pathological microenvironment. Our results suggested that MSCs/PVLA could serve as a promising candidate to prevent disease exacerbations and treat refractory asthma.

01 Nov 2024·Molecular neurobiology

A Multistep In Silico Approach Identifies Potential Glioblastoma Drug Candidates via Inclusive Molecular Targeting of Glioblastoma Stem Cells

Article

Author: Dogra, Nilambra ; Singh, Parminder ; Kumar, Ashok

Glioblastoma (GBM) is the highest grade of glioma for which no effective therapy is currently available. Despite extensive research in diagnosis and therapy, there has been no significant improvement in GBM outcomes, with a median overall survival continuing at a dismal 15-18 months. In recent times, glioblastoma stem cells (GSCs) have been identified as crucial drivers of treatment resistance and tumor recurrence, and GBM therapies targeting GSCs are expected to improve patient outcomes. We used a multistep in silico screening strategy to identify repurposed candidate drugs against selected therapeutic molecular targets in GBM with potential to concomitantly target GSCs. Common differentially expressed genes (DEGs) were identified through analysis of multiple GBM and GSC datasets from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). For identification of target genes, we selected the genes with most significant effect on overall patient survival. The relative mRNA and protein expression of the selected genes in TCGA control versus GBM samples was also validated and their cancer dependency scores were assessed. Drugs targeting these genes and their corresponding proteins were identified from LINCS database using Connectivity Map (CMap) portal and by in silico molecular docking against each individual target using FDA-approved drug library from the DrugBank database, respectively. The molecules thus obtained were further evaluated for their ability to cross blood brain barrier (BBB) and their likelihood of resulting in drug resistance by acting as p-glycoprotein (p-Gp) substrates. The growth inhibitory effect of these final shortlisted compounds was examined on a panel of GBM cell lines and compared with temozolomide through the drug sensitivity EC50 values and AUC from the PRISM Repurposing Secondary Screen, and the IC50 values were obtained from GDSC portal. We identified RPA3, PSMA2, PSMC2, BLVRA, and HUS1 as molecular targets in GBM including GSCs with significant impact on patient survival. Our results show GSK-2126458/omipalisib, linifanib, drospirenone, eltrombopag, nilotinib, and PD198306 as candidate drugs which can be further evaluated for their anti-tumor potential against GBM. Through this work, we identified repurposed candidate therapeutics against GBM utilizing a GSC inclusive targeting approach, which demonstrated high in vitro efficacy and can prospectively evade drug resistance. These drugs have the potential to be developed as individual or combination therapy to improve GBM outcomes.

01 Jul 2024·JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Quantification and analyses of seven tyrosine kinase inhibitors targeting hepatocellular carcinoma in human plasma by QuEChERS and UPLC-MS/MS

Article

Author: Li, Yilin ; Song, Li ; Zhen, Xiaolan ; Li, Hui ; Liang, Yan ; Peng, Jiangning

Tyrosine kinase inhibitors (TKIs) are commonly used to treat various cancers. Literature suggests that the blood concentration of TKIs strongly correlates with their efficacy and adverse effects. Therefore, establishing a Therapeutic Drug Monitoring (TDM) methodology for TKI drugs is crucial to improving their clinical efficacy and minimizing the treatment-related adverse effects. However, quantifying their concentrations in the plasma using existing methods to avoid potential toxicity is challenging. Herein, seven TKIs, namely sorafenib tosylate, axitinib, erlotinib, cediranib, brivanib, linifanib, and golvatinib, were successfully analyzed in human plasma by following a quick, easy, cheap, effective, rugged, and safe (QuEChERS) pretreatment method combined with ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Briefly, biological samples were extracted using 1 mL of methanol, followed by the sequential addition of 250 mg of anhydrous magnesium sulfate and 25 mg of N-propylethylenediamine (PSA) for salinization and purification by adsorption, respectively. In this study, dovitinib was used as the internal standard. The seven TKIs were detected by the gradient elution method for 4 min in the positive ion electrospray mode. The mobile phase comprised methanol (phase A) and 0.1 % aqueous formic acid solution (phase B) on the Agilent Zorbax RRHD Stablebond Aq, (2.1 × 50 mm; 1.8 μm). Brivanib, linifanib, axitinib, sorafenib tosylate, and golvatinib exhibited good linearity in the range of 5-500 ng/mL, and erlotinib and cediranib exhibited good linearity in the range of 10-1000 ng/mL, with linear correlation coefficients (R²) ≥ 0.99. The limits of detection and quantification were 0.60-0.18 ng/mL and 5-10 ng/mL, respectively. The intraday and interday accuracy values ranged from -6.12 % to 7.31 %, with a precision (RSD) of ≤ 10.57 %. The method was rapid, accurate, specific, simple, reproducible, and suitable for the quantitative determination of the seven TKIs in human plasma.

News (Medical) associated with Linifanib

18 Sep 2023

·synapse.patsnap.com

Regulating tumor immune suppression, the therapeutic effect of the new generation CSF-1R inhibitors is encouraging

Colony-stimulating factor 1 (CSF-1), also known as macrophage colony-stimulating factor, is one of the most common proinflammatory cytokines leading to a variety of inflammatory diseases. It plays a significant role in the development and progression of osteoarthritis, cancer, and other autoimmune diseases. CSF-1 exerts its effects by binding to a receptor called colony stimulating factor 1 receptor (CSF-1R), also known as c-FMS, leading to a signaling pathway cascade, resulting in cell proliferation and differentiation. Although CSF-1R appears to be the only receptor for CSF-1, IL-34 additionally binds to receptor protein-tyrosine phosphatase-zeta (RPTP-ζ) and the expression pattern of the ligand is also different. CSF-1R/c-FMS is overexpressed in macrophages within many tumors, and thus has been used as a promising target for drug treatment of cancer and inflammatory diseases. Some CSF-1R/c-FMS inhibitors, such as ABT-869, Imatinib, AG013736, JNJ-40346527, PLX3397, DCC-3014, and Ki20227 have been used to study the treatment of these diseases. CSF-1R inhibitors work by binding to CSF-1R, preventing active cells from the body from signaling, thereby impeding the progression of diseases. In recent years, scientists have explored a series of CSF-1R-targeting drugs based on this target. The research status of related products is mostly at the clinical phase I. Strategies for targeting CSF-1R can be divided into two types. They can use large molecule antibodies to target its CSF-1 ligand, or CSF-1R receptor, or design small molecules to target the kinase active region. CSF-1R Competitive LandscapeAccording to the data provided by Patsnap Synapse-Global Drug Intelligence Database: the following figure shows that as of 15 Sep 2023, there are a total of 60 CSF-1R drugs worldwide, from 99 organizations, covering 105 indications, and conducting 1135 clinical trials. 👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target. The analysis of the target CSF-1R reveals a competitive landscape with multiple companies actively involved in the development of drugs. Daiichi Sankyo Co., Ltd., Novartis AG, Hutchison MediPharma Ltd., C.H. Boehringer Sohn AG & Co. KG, Swedish Orphan Biovitrum AB, and JCR Pharmaceuticals Co., Ltd. are some of the companies with significant R&D progress. The drugs targeting CSF-1R have been approved for various indications, including Giant Cell Tumor of Tendon Sheath, Colorectal Cancer, Hepatocellular Carcinoma, and Non-Small Cell Lung Cancer. Small molecule drugs and monoclonal antibodies are the most rapidly progressing drug types, indicating intense competition. The United States, China, and Japan are leading in the development of drugs targeting CSF-1R, with China showing significant progress. Overall, the target CSF-1R presents a promising area for future development in the pharmaceutical industry. Phase III Clinical Trial of CSF-1R Inhibitor: Pimicotinib Pimicotinib is a small molecule drug that targets CSF-1R, a receptor involved in various diseases. It has shown potential therapeutic benefits in a wide range of therapeutic areas, including Nervous System Diseases, Endocrinology and Metabolic Disease, Neoplasms, Digestive System Disorders, Skin and Musculoskeletal Diseases, Respiratory Diseases, Immune System Diseases, and Other Diseases. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. The drug has been specifically indicated for the treatment of Giant Cell Tumor of Tendon Sheath, Chronic graft-versus-host disease, Lung Cancer, Pancreatic Cancer, Triple Negative Breast Cancer, and Amyotrophic Lateral Sclerosis. These indications cover a diverse range of conditions, highlighting the potential versatility of Pimicotinib in addressing various diseases. Pimicotinib is developed by Abbisko Therapeutics Co., Ltd., an originator organization in the pharmaceutical industry. The drug has reached the highest phase of clinical development, with Phase 3 trials being conducted globally. In terms of regulation, Pimicotinib has received PRIME (Priority Medicines) designation, which is a program by the European Medicines Agency (EMA) to accelerate the development of promising medicines for unmet medical needs. Additionally, the drug has been granted Breakthrough Therapy designation, a program by the U.S. Food and Drug Administration (FDA) that expedites the development and review of drugs that demonstrate substantial improvement over existing therapies for serious conditions. Overall, Pimicotinib is a small molecule drug that targets CSF-1R and has shown potential in various therapeutic areas. With its active indications covering diseases such as Giant Cell Tumor of Tendon Sheath, Chronic graft-versus-host disease, Lung Cancer, Pancreatic Cancer, Triple Negative Breast Cancer, and Amyotrophic Lateral Sclerosis, Pimicotinib holds promise as a versatile treatment option. Its progression to Phase 3 trials globally, along with regulatory designations such as PRIME and Breakthrough Therapy, further highlight its potential as an innovative therapeutic solution in the field of biomedicine.

13 Feb 2023

·www.biospace.com

Aethlon Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

SAN DIEGO, Feb. 13, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today reported financial results for its third quarter ended December 31, 2022 and provided an update on recent developments. Company Updates Aethlon Medical is continuing the research and clinical development of its Hemopurifier®, a therapeutic blood filtration system that can bind and remove harmful exosomes and life-threatening viruses from blood. This action has potential applications in cancer, where cancer associated exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Company recently contracted with NAMSA, LLC 2023 (NAMSA), , a world-leading MedTech CRO offering global end-to-end development services, to direct our planned oncology study in Australia and the United States. This new clinical trial in oncology is planned to be a safety, feasibility and dose finding trial in solid tumors failing anti-PD-1 antibodies. We believe that this trial will help inform the design of future efficacy trials of our Hemopurifier in oncology. The Company plans to initiate this trial first in Australia and then in the United States. We recently hired Lee Arnold, PhD, as our new Chief Scientific Officer. Dr. Arnold is a creative scientific leader with 36 years of accomplishments in molecularly-targeted drug discovery. After an initial eight publications in biophysics and biochemistry as an undergraduate at University of Waterloo, he earned a PhD in Organic Chemistry from University of Alberta. Dr. Arnold began his career in pharma research at Syntex, Inc. (Canada), and then joined Pfizer Inc., where he was the inventor of Tarceva® (erlotinib) for non-small cell lung cancer, or NSCLC. During his tenure at BASF/Abbott Bioresearch Center, he established medicinal & combinatorial chemistry operations, and initiated and led two multinational multidisciplinary projects in angiogenesis, ultimately leading to linifanib (ABT-869). As Vice President of Research at OSI Pharmaceuticals, Dr. Arnold and his teams discovered four oncology development candidates, including the "first-in-class" agents linsitinib (IGF-1R), and ASP7486 (TORC1/2). Dr. Arnold also has served as Chief Scientific Officer (CSO) in a number of innovative start-up biotechnology companies. Just prior to joining Aethlon Medical, Dr. Arnold was the CSO and cofounder of Pardes Biosciences, Inc., which was established at the start of the COVID pandemic as a virtual company that discovered and advanced the oral protease inhibitor, pomotrelvir, into clinical trials for SARS-CoV2 in only 17 months. Dr. Arnold's inventive and leadership contributions in drug discovery and development to date have resulted in an approved drug, and 16 additional development candidates, currently fueling eight clinical trials in oncology, immunology and virology. These achievements are documented in over 94 published patents and applications, and more than 39 peer-reviewed publications. Charles J. Fisher, Jr., MD, our Chief Executive Officer, stated "we are delighted to have Lee Arnold join our team. He has an extensive career in science and he has led the product development at five previous companies. We look forward to his active leadership of our research team." Our ongoing COVID-19 trial in India for patients in the ICU at Medanta Medicity Hospital continues to be open for enrollment with one patient treated to date. We also have ongoing preclinical studies to expand the potential utility of the Hemopurifier. These studies include the Monkeypox (mPox) experiment underway at Battelle Labs to examine the in vitro removal of the currently circulating strain of mPox by a miniature version of our Hemopurifier We also recently entered into a materials transfer agreement with the UCSF Medical Center for the study of Post-acute Sequelae of COVID-19 infection (PASC), also known as "Long COVID-19." In this study, we will receive plasma samples from patients with PASC, as well as from patients with prior COVID-19 without PASC symptoms. The objective of this study is to perform in vitro analysis of exosomes to determine the viability of PASC as a therapeutic target for the Hemopurifier. Financial Results for the Third Quarter Ended December 31, 2022 As of December 31, 2022, Aethlon Medical had a cash balance of approximately $17.5 million. Consolidated operating expenses for the three months ended December 31, 2022 were approximately $2.85 million, compared to $2.545 million for the three months ended December 31, 2021. This increase of approximately $305,000, or 12%, in the 2022 period was due to increases in professional fees of $296,000 and in payroll and related expenses of $49,000, offset by a decrease in general and administrative expenses of $40,000. The $296,000 increase in professional fees in the 2022 period was primarily due to the combination of a $145,000 increase in contract labor expense associated with product development and scientific analytical services, a $73,000 increase in scientific consulting expense, a $71,000 increase in legal fees, and a $22,000 increase associated with recruiting. These expenses were partially offset by a $14,000 decrease in accounting expenses. The $49,000 increase in our payroll and related expenses in the 2022 period was due to an increase of $167,000 in salary expense and an increase of $62,000 of stock-based compensation expense related to increased headcount, offset by a decrease of $180,000 in relocation expense. The $40,000 decrease in administrative expenses in the 2022 period was primarily due to a $75,000 decrease in clinical trial expenses, a $19,000 decrease in rent expense and a $20,000 decrease in licenses and permits, which was partially offset by a $60,000 increase in depreciation expense. Aethlon did not record government contract revenue in the three months ended December 31, 2022. We recorded $17,117 in government contract revenue in the three months ended December 31, 2021. As of December 31, 2022, the Company had approximately $574,000 of deferred revenue related to those government contracts as a result of not achieving certain milestones in the contracts. The NIH award contract ended on September 15, 2022 and we presented the required final report to the NCI. Once the NCI completes the close out review of the contract, we expect to recognize as revenue the $574,000 currently recorded as deferred revenue on our December 31, 2022 balance sheet. As a result of the changes in revenues and expenses noted above, our net loss increased to approximately $2,850,000 in the three months ended December 31, 2022, from approximately $2,528,000 in the three months ended December 31, 2021. During the nine months ended December 31, 2022, the Company raised approximately $8.9 million in net proceeds under our ATM agreement with H.C. Wainwright & Co., pursuant to sales of our common stock. The unaudited condensed consolidated balance sheet for December 31, 2022, and the unaudited condensed consolidated statements of operations for the three and nine months ended December 31, 2022 and 2021 follow at the end of this release. Conference Call The Company will hold a conference call today, Monday, February 13, 2022, at 4:30 p.m. EST to review financial results and recent corporate developments. Following management's formal remarks, there will be a question-and-answer session. Interested parties can register for the conference by navigating to . Please note that registered participants will receive their dial in number upon registration. Interested parties without internet access or unable to pre-register may dial in by calling: All callers should ask for the Aethlon Medical, Inc. conference call. A replay of the call will be available approximately one hour after the end of the call through March 13, 2023. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 4716809. About Aethlon and the Hemopurifier® Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device designed to combat cancer and life-threatening viral infections, as its lead technology. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing a proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open IDE application related to the treatment of life-threatening viruses that are not addressed with approved therapies. Additional information can be found at . Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to launch its clinical trials in Australia and in the United States and expand its trials in India, the Company's ability to obtain FDA approval of its new GNA supplier in a timely manner, the Company's ability to submit to the FDA and have the FDA approve an EUA for the Mpox virus, the Company's ability to successfully treat patients under any Emergency Use pathway, the Company's ability to successfully complete development of its Hemopurifier, the Company's ability to raise additional funds, and the Company's ability expand its clinical trials into other areas of cancer, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2022, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. Company Contact: Jim Frakes Chief Financial Officer Aethlon Medical, Inc. Jfrakes@aethlonmedical.com Investor Contact: Susan Noonan S.A. Noonan Communications, LLC susan@sanoonan.com 917-513-5303 View original content: SOURCE Aethlon Medical, Inc. Company Codes: NASDAQ-SMALL:AEMD

Financial StatementExecutive ChangeClinical Study

100 Deals associated with Linifanib

External Link

KEGG	Wiki	ATC	Drug Bank
D09635	Linifanib	-	DB06080

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Hepatocellular Carcinoma	Phase 3	United States	Abbott Laboratories	01 Jan 2010
Advanced Hepatocellular Carcinoma	Phase 3	China	Abbott Laboratories	01 Jan 2010
Advanced Hepatocellular Carcinoma	Phase 3	Japan	Abbott Laboratories	01 Jan 2010
Advanced Hepatocellular Carcinoma	Phase 3	Argentina	Abbott Laboratories	01 Jan 2010
Advanced Hepatocellular Carcinoma	Phase 3	Australia	Abbott Laboratories	01 Jan 2010
Advanced Hepatocellular Carcinoma	Phase 3	Austria	Abbott Laboratories	01 Jan 2010
Advanced Hepatocellular Carcinoma	Phase 3	Belgium	Abbott Laboratories	01 Jan 2010
Advanced Hepatocellular Carcinoma	Phase 3	Canada	Abbott Laboratories	01 Jan 2010
Advanced Hepatocellular Carcinoma	Phase 3	Chile	Abbott Laboratories	01 Jan 2010
Advanced Hepatocellular Carcinoma	Phase 3	Czechia	Abbott Laboratories	01 Jan 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01009593 (Pubmed \| J Urol \| J Clin Oncol) Manual	Phase 3	Advanced Hepatocellular Carcinoma	1,035	Linifanib	odvbebpwde(iiqmkiyueq) = frmfglzeri dtkbqmevbn (rsjjttjdor, 8.1 - 10.2) View more	Similar	10 Jan 2015
NCT01009593 (Pubmed \| J Urol \| J Clin Oncol) Manual	Phase 3	Advanced Hepatocellular Carcinoma	1,035	sorafenib	odvbebpwde(iiqmkiyueq) = qxvrrjjztb dtkbqmevbn (rsjjttjdor, 8.3 - 11.0) View more	Similar	10 Jan 2015
NCT01365910 (CTgov)	Phase 2	Recurrent Colon Cancer \| Rectal Cancer \| Refractory Colorectal Carcinoma	30	linifanib	lomqdhqrnt(devqsawmoi) = ybkjvltvho tjhycfnjbr (upuqaebkem, grlkfqsbzo - uampvkyilg) View more	-	26 Aug 2014
NCT01225302 (Pubmed \| Cancer Chemother Pharmacol)	Phase 1	metastatic non-small cell lung cancer First line	12	Linifanib	rdgvhqaiub(xmfbahfyjh) = pairgdvita cdlizpjvzp (kfnaknlpvg ) View more	-	01 Jul 2014
NCT00733187 (Pubmed \| Cancer Chemother Pharmacol)	Phase 1	Solid tumor	24	Linifanib	xsqaztrajc(xdxsafcbhd) = sxhblcuupb hheigotukk (omsgppovzw )	Positive	01 Jan 2014
ASCO2010	Phase 2	Non-Small Cell Lung Cancer	139	Linifanib 0.10 mg/kg	pnpgjreeal(gnqqxgdasy) = cuigrxoomc nfgbkcuzhu (rsboovzyzr ) View more	-	20 May 2010
ASCO2010	Phase 2	Non-Small Cell Lung Cancer	139	Linifanib 0.25 mg/kg	pnpgjreeal(gnqqxgdasy) = zejvqtztgh nfgbkcuzhu (rsboovzyzr ) View more	-	20 May 2010
ASCO2010	Phase 2	Advanced Renal Cell Carcinoma	53	Linifanib 0.25 mg/kg	thalxebwmq(vpepekbxac) = nwcupbewok ianxsrtxwt (qyogphwoxy, [3.1 - 20.7]) View more	-	20 May 2010
ASCO2010	Phase 2	Advanced Hepatocellular Carcinoma	44	Linifanib 0.25 mg/kg QD	exdzyqxjez(uzfpzzaefm) = feycjtvsqj exbrdiqgbo (mwftioqoen ) View more	-	20 May 2010
ASCO2009	Phase 2	Advanced Renal Cell Carcinoma	53	ABT-869	exidgumjlx(tclopimfbd) = nmntjaldvj eihnergpeo (lpvipoqitp, 3.5–6.8)	-	20 May 2009
ASCO2009	Phase 2	Non-Small Cell Lung Cancer	138	ABT-869 0.10 mg/kg daily	wyxdhubngp(swiauyjbqg) = pqhdmkeuba bcfyxewwox (xppubbzblw ) View more	-	20 May 2009
ASCO2009	Phase 2	Non-Small Cell Lung Cancer	138	ABT-869 0.25 mg/kg daily	ddlfszjenp(wiklpmqild) = ymbuflvhyf buypeclyfe (nrwiacyojt ) View more	-	20 May 2009
M06–879 (ASCO2009)	Phase 2	Hepatocellular Carcinoma	44	ABT-869 0.25 mg/kg daily	dgezjdugyq(mohvcqaban) = whqkqskqoo mbxdyfoldx (udlzeovgza, 1.1 - 28) View more	-	20 May 2009

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis